DE69911058D1 - Kombinationen einem ibat inhibitor und einem mtp inhibitor für kardiovaskuläre indikationen - Google Patents

Kombinationen einem ibat inhibitor und einem mtp inhibitor für kardiovaskuläre indikationen

Info

Publication number
DE69911058D1
DE69911058D1 DE69911058T DE69911058T DE69911058D1 DE 69911058 D1 DE69911058 D1 DE 69911058D1 DE 69911058 T DE69911058 T DE 69911058T DE 69911058 T DE69911058 T DE 69911058T DE 69911058 D1 DE69911058 D1 DE 69911058D1
Authority
DE
Germany
Prior art keywords
inhibitor
combinations
ibat
mtp
cardiovascular indications
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69911058T
Other languages
English (en)
Other versions
DE69911058T2 (de
Inventor
T Keller
B Reitz
R Schuh
A Sikorski
J Tremont
W Lappe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GD Searle LLC
Original Assignee
GD Searle LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22352512&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69911058(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by GD Searle LLC filed Critical GD Searle LLC
Publication of DE69911058D1 publication Critical patent/DE69911058D1/de
Application granted granted Critical
Publication of DE69911058T2 publication Critical patent/DE69911058T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
DE69911058T 1998-12-23 1999-12-17 Kombinationen einem ibat inhibitor und einem mtp inhibitor für kardiovaskuläre indikationen Expired - Fee Related DE69911058T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11395598P 1998-12-23 1998-12-23
US113955P 1998-12-23
PCT/US1999/027946 WO2000038725A1 (en) 1998-12-23 1999-12-17 Combinations for cardiovascular indications

Publications (2)

Publication Number Publication Date
DE69911058D1 true DE69911058D1 (de) 2003-10-09
DE69911058T2 DE69911058T2 (de) 2004-06-03

Family

ID=22352512

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69911058T Expired - Fee Related DE69911058T2 (de) 1998-12-23 1999-12-17 Kombinationen einem ibat inhibitor und einem mtp inhibitor für kardiovaskuläre indikationen

Country Status (23)

Country Link
US (1) US20040058908A1 (de)
EP (2) EP1140187B1 (de)
JP (1) JP2002533411A (de)
KR (1) KR20020002367A (de)
CN (1) CN1342091A (de)
AR (1) AR037482A1 (de)
AT (1) ATE248606T1 (de)
AU (1) AU779264B2 (de)
BR (1) BR9916564A (de)
CA (1) CA2356515A1 (de)
CZ (1) CZ20012344A3 (de)
DE (1) DE69911058T2 (de)
DK (1) DK1140187T3 (de)
EA (1) EA200100704A1 (de)
ES (1) ES2207330T3 (de)
HU (1) HUP0104655A2 (de)
IL (1) IL143944A0 (de)
MX (1) MXPA01006468A (de)
NO (1) NO20013157L (de)
NZ (1) NZ512532A (de)
PT (1) PT1140187E (de)
WO (1) WO2000038725A1 (de)
ZA (5) ZA200105056B (de)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221897B1 (en) 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
US6699508B1 (en) * 1998-08-10 2004-03-02 Asahi Kasei Pharma Corporation Sustained release oral preparations of fasudil hydrochloride
SE0000772D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab Chemical compounds
AU2001247331A1 (en) * 2000-03-10 2001-09-24 Pharmacia Corporation Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
AR030414A1 (es) * 2000-04-03 2003-08-20 Astrazeneca Ab Combinacion farmaceutica que comprende un beta bloqueante y un inhibidor de hmg-coa reductasa , formulacion farmaceutica, equipo transportable de partes , uso de esta combinacion y de esta formulacion para preparar medicamentos
PL357674A1 (en) * 2000-04-19 2004-07-26 Thomas Julius Borody Compositions and therapies for hyperlipidaemia-associated disorders
SE0002354D0 (sv) * 2000-06-22 2000-06-22 Astrazeneca Ab New formulation
EG26979A (en) 2000-12-21 2015-03-01 Astrazeneca Ab Chemical compounds
AU2006203175B2 (en) * 2001-01-26 2008-07-24 Organon Llc Combinations of peroxisome proliferator-activated receptor (PPAR) activators(s) and sterol absorption inhibitors(s) and treatments for vascular indications
TW200840563A (en) * 2001-01-26 2008-10-16 Schering Corp Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(S) and treatments for vascular indications
AU2007201970B2 (en) * 2001-01-26 2008-04-17 Organon Llc Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
SI1353696T1 (sl) * 2001-01-26 2007-04-30 Schering Corp Kombinacije aktivatorja(-ev) peroksisomskega proliferatorja aktivirajocega receptorja (PPAR) in inhibitorja(-ev) absorpcije sterola in oblike zdravljenja za vaskularne indikacije
AU2006202618B2 (en) * 2001-01-26 2007-04-19 Organon Llc Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
ES2287250T3 (es) * 2001-01-26 2007-12-16 Schering Corporation Combinaciones de secuestrante(s) de acidos biliares e inhibidor(es) de la absorcion de esteroles y tratamientos para indicaciones vasculares.
CN101297969B (zh) * 2001-01-26 2011-03-09 先灵公司 过氧化物酶体增殖物激活受体(ppar)活化剂和甾醇吸收抑制剂的组合药
EP1911462A3 (de) 2001-01-26 2011-11-30 Schering Corporation Zusammensetzungen enthaltend einen Sterolabsorptionshemmer
CZ20032031A3 (cs) * 2001-01-26 2003-12-17 Schering Corporation Farmaceutický prostředek
CA2439920A1 (en) * 2001-03-08 2002-09-19 Merck & Co., Inc. Antihypertensive agent and cholesterol absorption inhibitor combination therapy
EP1269994A3 (de) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmazeutische Zusammensetzungen die ein Arzneimittel und die Konzentration verbesserende Polymere enthalten
EP1425018B1 (de) * 2001-08-22 2008-10-22 Sanofi-Aventis Deutschland GmbH Kombinationspräparate von 1,4- benzothiepin-1,1-dioxidderivaten mit weiteren wirkstoffen und deren verwendung
KR20040027963A (ko) * 2001-08-22 2004-04-01 아벤티스 파마 도이칠란트 게엠베하 아릴 치환된 프로판올아민 유도체와 다른 활성 성분과의배합 제제 및 이의 용도
GB0121337D0 (en) 2001-09-04 2001-10-24 Astrazeneca Ab Chemical compounds
GB0121622D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
GB0121621D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
EP1427423B9 (de) 2001-09-08 2017-12-20 AstraZeneca AB Benzothiazepin und benzothiadiazepin derivative mit hemmender wirkung auf den säuretransport in den gallengängen zur behandlung von hyperlipidaemia
US7094801B2 (en) 2001-12-19 2006-08-22 Atherogenics, Inc. Chalcone derivatives and their use to treat diseases
AU2002361811A1 (en) 2001-12-19 2003-07-09 Atherogenics, Inc. 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
EP1465885A4 (de) * 2002-01-17 2005-04-27 Pharmacia Corp Neue alkyl/arylhydroxy- oder ketothiepin-verbindungen als hemmer des apikalen natriumcoabhängigen gallensäuretransports (asbt) und taurocholat-aufnahme
BR0308494A (pt) * 2002-03-18 2005-05-03 Pharmacia Corp Combinação de um antagonista de receptores de aldosterona e de um derivado do ácido fìbrico
CA2479259A1 (en) * 2002-03-18 2003-10-02 Pharmacia Corporation Combination of an aldosterone receptor antagonist and a bile acid sequestering agent
GB0209467D0 (en) 2002-04-25 2002-06-05 Astrazeneca Ab Chemical compounds
GB0213669D0 (en) 2002-06-14 2002-07-24 Astrazeneca Ab Chemical compounds
GB0215579D0 (en) 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
WO2004041288A1 (en) * 2002-11-05 2004-05-21 Schering Aktiengesellschaft Hormone replacement therapy with drospirenone
US7786101B2 (en) 2002-11-05 2010-08-31 Bayer Schering Pharma Ag Cardiovascular protection using anti-aldosteronic progestins
GB0304194D0 (en) 2003-02-25 2003-03-26 Astrazeneca Ab Chemical compounds
GB0307918D0 (en) 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use
AR041089A1 (es) 2003-05-15 2005-05-04 Merck & Co Inc Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
DE602004029715D1 (de) 2003-12-23 2010-12-02 Astrazeneca Ab Diphenylazetidinonderivate mit die cholesterinabsorption hemmender wirkung
KR101494067B1 (ko) 2004-03-05 2015-02-16 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 부작용을 최소화하면서 과지질혈증 및 과콜레스테롤혈증과 연관된 질환 또는 질병의 치료 방법
US20060211752A1 (en) 2004-03-16 2006-09-21 Kohn Leonard D Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
CA2553309A1 (en) 2004-04-22 2005-11-03 Mor Research Applications Ltd. Method of food intake management
US7728015B2 (en) 2004-04-22 2010-06-01 Mor Research Applications Ltd. Compositions for weight management
CA2578224A1 (en) * 2004-08-25 2006-03-09 Essentialis, Inc. Pharmaceutical formulations of potassium atp channel openers and uses thereof
SA06270191B1 (ar) 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
EP1948163A2 (de) * 2005-10-18 2008-07-30 Aegerion Pharmaceuticals Verfahren zur behandlung von erkrankungen im zusammenhang mit hyperlipidämie bei säugetieren
US20080255084A1 (en) 2005-10-21 2008-10-16 Randy Lee Webb Combination of Organic Compounds
JP5192392B2 (ja) * 2005-12-30 2013-05-08 メルク・シャープ・エンド・ドーム・コーポレイション コレステリルエステル転送タンパク質阻害剤
JP5543110B2 (ja) 2006-01-05 2014-07-09 エッセンシャリス，インク． カリウムａｔｐチャネルオープナの塩およびその使用
AR060623A1 (es) 2006-04-27 2008-07-02 Astrazeneca Ab Compuestos derivados de 2-azetidinona y un metodo de preparacion
JP2010513534A (ja) * 2006-12-21 2010-04-30 エージェリオン ファーマシューティカルズ， インコーポレイテッド Ｍｔｐインヒビターおよびコレステロール吸収インヒビターを含む組み合わせを用いて肥満症を処置する方法
CA2692160A1 (en) * 2007-07-02 2009-01-08 Essentialis, Inc. Salts of potassium atp channel openers and uses thereof
US20090197947A1 (en) * 2008-02-01 2009-08-06 The Research Foundation Of State University Of New York Medicaments and methods for lowering plasma lipid levels and screening drugs
NZ595789A (en) 2009-04-29 2014-05-30 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
EP2995317A1 (de) 2010-05-26 2016-03-16 Satiogen Pharmaceuticals, Inc. Gallensäurerückflusshemmer zur behandlung von diabetes, adipositas und entzündlichen magen-darm-erkrankungen
RU2619215C2 (ru) 2010-11-08 2017-05-12 Альбирео Аб Фармацевтическая комбинация, включающая ibat-ингибитор и связующее желчной кислоты
ES2586931T3 (es) 2010-11-08 2016-10-19 Albireo Ab Inhibidores de IBAT para el tratamiento de enfermedades hepáticas
JP2012171911A (ja) 2011-02-22 2012-09-10 Kao Corp Ｐｐａｒ活性化剤
EA038594B1 (ru) 2011-10-28 2021-09-21 Шайр Хьюман Дженетик Терапис, Инк. Ингибиторы рециркуляции желчных кислот для лечения гиперхолемии и холестатического заболевания печени
SG10201909122QA (en) 2011-10-28 2019-11-28 Lumena Pharmaceuticals Inc Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
US8864587B2 (en) 2012-10-03 2014-10-21 Sony Corporation User device position indication for security and distributed race challenges
WO2014144485A1 (en) 2013-03-15 2014-09-18 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of barrett's esophagus and gastroesophageal reflux disease
CA2907230A1 (en) 2013-03-15 2014-09-18 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease
JO3301B1 (ar) 2013-04-26 2018-09-16 Albireo Ab تعديلات بلورية على إيلوبيكسيبات
US20150079562A1 (en) 2013-09-17 2015-03-19 Sony Corporation Presenting audio based on biometrics parameters
US9269119B2 (en) 2014-01-22 2016-02-23 Sony Corporation Devices and methods for health tracking and providing information for improving health
US10709755B2 (en) 2014-06-25 2020-07-14 Elobix Ab Solid formulation and method for preventing or reducing coloration thereof
EP3012252A1 (de) 2014-10-24 2016-04-27 Ferring BV Kristalline Form von elobixibat
CA3011565C (en) 2016-02-09 2024-01-02 Albireo Ab Oral cholestyramine formulation and use thereof
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
CN108601745B (zh) 2016-02-09 2021-12-07 阿尔比里奥公司 口服考来烯胺制剂及其用途
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
CA3071182A1 (en) 2017-08-09 2019-02-14 Albireo Ab Cholestyramine pellets, oral cholestyramine formulations and use thereof
WO2019032026A1 (en) 2017-08-09 2019-02-14 Albireo Ab CHOLESTYRAMINE GRANULES, ORAL FORMULATIONS OF CHOLESTYRAMINE AND THEIR USE
CN112449637B (zh) 2018-06-05 2024-03-19 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
JP7448490B2 (ja) 2018-06-20 2024-03-12 アルビレオ・アクチボラグ オデビキシバットの医薬製剤
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
MX2021008981A (es) 2019-02-06 2021-09-08 Albireo Ab Compuestos de benzotiadiazepina y su uso como moduladores del acido biliar.
WO2020161216A1 (en) 2019-02-06 2020-08-13 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
MX2021009625A (es) 2019-02-12 2021-11-04 Mirum Pharmaceuticals Inc Métodos para incrementar el crecimiento en sujetos pediátricos que tienen enfermedad de hígado colestásico.
CN111789843A (zh) * 2019-04-08 2020-10-20 深圳奥萨医药有限公司 含氨氯地平、氯噻酮和阿米洛利的药物组合物
CA3158184A1 (en) 2019-12-04 2021-08-10 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
WO2021110887A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
WO2021110884A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
JP2023504643A (ja) 2019-12-04 2023-02-06 アルビレオ・アクチボラグ ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
JP2023504647A (ja) 2019-12-04 2023-02-06 アルビレオ・アクチボラグ ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
TW202134221A (zh) 2019-12-04 2021-09-16 瑞典商艾爾比瑞歐公司 苯并噻二氮呯化合物及其作為膽酸調節劑之用途
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
WO2021110883A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
FI4069360T3 (fi) 2019-12-04 2024-02-20 Albireo Ab Bentsotia(di)atsepiinin yhdisteet ja niiden käyttö sappihapon modulaattoreina
TW202134220A (zh) 2019-12-04 2021-09-16 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
JP2023537285A (ja) 2020-08-03 2023-08-31 アルビレオ・アクチボラグ ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
EP4243831A1 (de) 2020-11-12 2023-09-20 Albireo AB Odevixibat zur behandlung von progressiver familiärer intrahepatischer cholestase (pfic)
CN116583504A (zh) 2020-12-04 2023-08-11 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
WO2023237728A1 (en) 2022-06-09 2023-12-14 Albireo Ab Treating hepatitis
WO2024064630A1 (en) * 2022-09-19 2024-03-28 M2Sp Llc Treatment for heart failure with preserved ejection fraction with guanethidine and guanadrel

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB860303A (en) * 1958-06-20 1961-02-01 Ici Ltd Pharmaceutical compositions comprising ª‡-aryloxy-aliphatic carboxylic acids and/or ª
US3287370A (en) * 1965-06-08 1966-11-22 Mcneilab Inc Tetrahydrobenzothiepins
US3389144A (en) * 1965-06-08 1968-06-18 Mcneilab Inc 5-pyridyl-2, 3, 4, 5-tetrahydrobenzothiepin-5-ols
US3444176A (en) * 1967-04-28 1969-05-13 Mcneilab Inc Certain 4-diloweralkylamino-lower alkyl - 5 - pyridyl (or phenyl)-2,3-dihydro - 1 - benzothiepins and derivatives thereof
US3674836A (en) * 1968-05-21 1972-07-04 Parke Davis & Co 2,2-dimethyl-{11 -aryloxy-alkanoic acids and salts and esters thereof
US4058552A (en) * 1969-01-31 1977-11-15 Orchimed Sa Esters of p-carbonylphenoxy-isobutyric acids
FR2077733B1 (de) * 1970-02-10 1973-03-16 Roussel Uclaf
US3694446A (en) * 1970-02-24 1972-09-26 William J Houlihan 5-(substituted-benzyl)-benzocycloheptenes and-1-benzthiepines
US3692895A (en) * 1970-09-08 1972-09-19 Norman A Nelson Method of reducing hypercholesteremia in humans employing a copolymer of polyethylenepolyamine and a bifunctional substance, such as epichlorohydria
DE2230383C3 (de) * 1971-10-01 1981-12-03 Boehringer Mannheim Gmbh, 6800 Mannheim Phenoxyalkylcarbonsäurederivate und Verfahren zur Herstellung derselben
US4002750A (en) * 1972-04-28 1977-01-11 Carlo Erba S.P.A. Pyrazine 4-oxide derivatives and process for their preparation
US3948973A (en) * 1972-08-29 1976-04-06 Sterling Drug Inc. Halocyclopropyl substituted phenoxyalkanoic acids
US3962261A (en) * 1974-02-04 1976-06-08 Warner-Lambert Company 2,3,4,5-tetra hydro-5-oxo-1-benzothiepi n-4-carboxamide 1,1-dioxides
FR2260569B1 (de) * 1974-02-08 1978-06-16 Ugine Kuhlmann
JPS5612114B2 (de) * 1974-06-07 1981-03-18
SE420725B (sv) * 1974-09-26 1981-10-26 Ciba Geigy Ag Sett att framstella 2,3-dihydro-1-benstiepin-4-karboxylsyraamider
US4251526A (en) * 1977-10-31 1981-02-17 Mccall John M 2-Benzothiepins and compositions and methods of use therefore
US4231938A (en) * 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) * 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
DK149080C (da) * 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
US5354772A (en) * 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US4559332A (en) * 1983-04-13 1985-12-17 Ciba Geigy Corporation 20-Spiroxanes and analogues having an open ring E, processes for their manufacture, and pharmaceutical preparations thereof
US5158943A (en) * 1988-11-21 1992-10-27 Takeda Chemical Industries, Ltd. Sulfur-containing heterocyclic compounds
US5075293A (en) * 1989-10-10 1991-12-24 The Dow Chemical Company ((N-heterocyclyl)carbonyl)phosphoramidothioate ester insecticides
US5153184A (en) * 1989-10-10 1992-10-06 Dowelanco ((N-heterocyclyl)carbonyl)phosphoramidothioate ester insecticides
PL166991B1 (pl) * 1991-05-03 1995-07-31 Raision Margariini Oy Sposób wytwarzania substancji obnizajacej poziom cholesterolu w surowicy krwi PL PL PL
US5260316A (en) * 1991-07-30 1993-11-09 Ciba-Geigy Corporation Isoquinolyl substituted hydroxylamine derivatives
US5334600A (en) * 1991-07-30 1994-08-02 Ciba-Geigy Corporation Isoquinolyl substituted hydroxylamine derivatives
US5350761A (en) * 1991-07-30 1994-09-27 Ciba-Geigy Corporation Indolyl substituted hydroxylamine derivatives
US5519001A (en) * 1991-12-19 1996-05-21 Southwest Foundation For Biomedical Research CETP inhibitor polypeptide antibodies against the synthetic polypeptide and prophylactic and therapeutic anti-atherosclerosis treatments
AU653658B2 (en) * 1991-12-20 1994-10-06 Hoechst Aktiengesellschaft Polymers and oligomers of bile acid derivatives, process for their preparation and their use as pharmaceuticals
US5244887A (en) * 1992-02-14 1993-09-14 Straub Carl D Stanols to reduce cholesterol absorption from foods and methods of preparation and use thereof
GB9203347D0 (en) * 1992-02-17 1992-04-01 Wellcome Found Hypolipidaemic compounds
FR2698873B1 (fr) * 1992-12-07 1995-02-24 Lipha Benzocycloheptènes, benzoxépines et benzothiépines activateurs des canaux potassiques, procédé de préparation, composition pharmaceutique les contenant.
WO1994009774A1 (en) * 1992-10-26 1994-05-11 Merck & Co., Inc. Biologically active compounds and process therefor
IL108633A (en) * 1993-02-15 1998-07-15 Wellcome Found History of Benzothiazepine Hypolipidemic Preparation and Pharmaceutical Preparations Containing Them
TW289021B (de) * 1993-05-08 1996-10-21 Hoechst Ag
TW289020B (de) * 1993-05-08 1996-10-21 Hoechst Sktiengesellschaft
US5703188A (en) * 1993-06-02 1997-12-30 Geltex Pharmaceuticals, Inc. Process for removing bile salts from a patient and compositions therefor
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5994391A (en) * 1994-09-13 1999-11-30 G.D. Searle And Company Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
CN1084741C (zh) * 1994-09-13 2002-05-15 孟山都公司 具有回肠胆汁酸转运和牛磺胆酸盐摄入抑制剂作用的新的苯并硫杂䓬
US5705524A (en) * 1994-11-04 1998-01-06 Gilead Sciences, Inc. Thiepane compounds
US6034118A (en) * 1994-11-04 2000-03-07 Gilead Sciences, Inc. Thiepane compounds
AU716151B2 (en) * 1996-11-27 2000-02-17 Pfizer Inc. Apo B-secretion/MTP inhibitory amides
DK0864582T3 (da) * 1997-03-14 2003-09-29 Aventis Pharma Gmbh Hypolidemiske 1,4-benzothiazepin-1,1-dioxider
US5929062A (en) * 1997-06-19 1999-07-27 University Of Western Ontario Oxysterol inhibition of dietary cholesterol uptake

Also Published As

Publication number Publication date
NO20013157L (no) 2001-08-22
EP1140187A1 (de) 2001-10-10
EP1140187B1 (de) 2003-09-03
HUP0104655A2 (hu) 2002-04-29
ES2207330T3 (es) 2004-05-16
ZA200105060B (en) 2002-09-20
BR9916564A (pt) 2002-01-29
MXPA01006468A (es) 2004-03-10
CN1342091A (zh) 2002-03-27
ZA200105059B (en) 2002-06-20
AR037482A1 (es) 2004-11-17
ZA200105061B (en) 2002-06-20
US20040058908A1 (en) 2004-03-25
KR20020002367A (ko) 2002-01-09
ATE248606T1 (de) 2003-09-15
WO2000038725A1 (en) 2000-07-06
NO20013157D0 (no) 2001-06-22
DK1140187T3 (da) 2003-12-22
ZA200105062B (en) 2002-08-28
CA2356515A1 (en) 2000-07-06
EA200100704A1 (ru) 2002-02-28
JP2002533411A (ja) 2002-10-08
AU2157700A (en) 2000-07-31
PT1140187E (pt) 2004-01-30
EP1354604A1 (de) 2003-10-22
CZ20012344A3 (cs) 2002-01-16
IL143944A0 (en) 2002-04-21
AU779264B2 (en) 2005-01-13
ZA200105056B (en) 2002-06-20
NZ512532A (en) 2003-12-19
DE69911058T2 (de) 2004-06-03

Similar Documents

Publication Publication Date Title
ATE248606T1 (de) Kombinationen einem ibat inhibitor und einem mtp inhibitor für kardiovaskuläre indikationen
ATE228012T1 (de) Kombinationen von ileumgallensäuretransports inhibitoren und gallensäure sequestriermitteln für kardiovaskuläre indikationen
ATE240120T1 (de) Kombinationen von ileumgallensäuretransports inhibitoren und fibronsäure derivaten für kardiovaskuläre indikationen
DE69903661T2 (de) Kombinationen von ileumgallensäuretransports inhibitoren und nicotinsäure derivaten für kardiovaskuläre indikationen
DE69923067D1 (de) Stentplazierinstrument und verfahren zum beladen
ID22690A (id) Metoda dan peralatan untuk pengukuran volume
DE69812122D1 (de) Verfahren und schaltung zur kalibrierung paralleller analog-digital-wandler
PL343269A1 (en) Alpha-ketoamide inhibitors of 20s proteasome
BR9605113A (pt) Sonda para imersão em metal fundido
GB9828109D0 (en) Inspection equipment and methods of inspection
DE69731038D1 (de) Screening-test zur identifikation von inhibitoren des makrophagenmigrationshemmenden faktors
DE69943407D1 (de) Prüfung von Vorrichtungsgehäusen
DE69704001D1 (de) Dämpfungsstifte für Deckbänder von Turbomaschinen
DE60021663D1 (de) Passivierungsätzmittel für metallpartikel
DE69913615D1 (de) Neutrale Rostinhibitore enthaltende Turbin- und R&O-Öle
NO982074D0 (no) FremgangsmÕte og instrument for nivÕmÕling
DE59706964D1 (de) Schaltungsanordnung zur messtechnischen bestimmung von durchmessern metallischer körper
DE9403540U1 (de) Tauchsonde
DE69518034D1 (de) Verfahren und Anordnung für einen Analog-Digital-Konverter
DE59914121D1 (de) Verfahren und Anordnung zur Ermittlung der Leerlaufspannung einer Batterie
DE69926427D1 (de) Verwaltung der Grundfrequenzmarkierungen für Sprachsynthese
KR970016396U (ko) 금속재의 산화 스케일 제거 시험장치
AU3148500A (en) Scale and corrosion inhibitor
ITBO960302A0 (it) Sonda di tastaggio
ITBO940577A0 (it) Sonda di tastaggio

Legal Events

Date Code Title Description
8363 Opposition against the patent
8339 Ceased/non-payment of the annual fee